Aflibercept (VEGF-TRAP): The next anti-VEGF drug

Inflammation and Allergy - Drug Targets

Volumn 10, Issue 6, 2011, Pages 497-508

  Stewart, Michael W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aflibercept; Angiogenesis; Fusion protein; Neovascularization; Oncology; Ophthalmology; Vascular endothelial growth factor; VEGF; VEGF TRAP

Indexed keywords

AFLIBERCEPT; DOCETAXEL; FLUOROURACIL; IRINOTECAN; PREDNISONE; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG APPROVAL; DRUG INDICATION; EXUDATIVE MACULAR DEGENERATION; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PANCREAS CARCINOMA; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CARCINOMA; RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; RETINITIS; RETROLENTAL FIBROPLASIA; SUBRETINAL NEOVASCULARIZATION; TUMOR GROWTH; VISUAL ACUITY;

EID: 81155126233     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152811798104872     Document Type: Article

References (104)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 1971, 285, 1182-1186.
2. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 1983, 12, 983-985.
3. Ferrara, N.; Henzel, W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun., 1989, 161, 851-858.
4. Tomanek, R.; Ishii, Y.; Holifield, J.S.; Sjogren, C.L.; Hansen, H.K.; Mikawa, T. VEGF family members regulate myocardial tubulogenesis and coronary artery formation in the embryo. Circ. Re., 2006, 98, 947-953.
5. Nguyen, Q.D.; Shah, S.M.; Browning, D.J.; Hudson, H.; Sonkin, P.; Hariprasad, S.M.; Kaiser, P.; Slakter, J.S.; Haller, J.; Do, D.V.; Mieler, W.F.; Chu, K.; Yang, K.; Ingerman, A.; Vitti, R.L.; Berliner, A.J.; Cedarbaum, J.M.; Campochiaro, P.A. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology, 2009, 116, 2141-2148.
6. Cao, J.; Zhao, L.; Li, Y.; Liu, Y.; Xiao, W.; Song, Y.; Luo, L.; Huang, D.; Yancopoulos, G.D.; Wiegand, S.J.; Wen, R. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF Trap. Invest. Ophthalmol. Vis. Sci., 2010, 51(11), 6009-6017.
7. Ferrara, N.; Gerber, H.P.; Lecouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9(6), 669-676.
8. Bhagat, N.; Grigorian, R.A.; Tutela, A.; Zarbin, M.A. Diabetic macular edema: pathogenesis and treatment. Surv. Ophthalmol., 2009, 54(1), 1-32.
9. Houck, K.A.; Leung, D.W.; Rowland, A.M.; Winer, J.; Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem., 1992, 267, 26031-26037.
10. Xiujun, F.; Sacha, K.; Calvin, J. K.; Stanley, J. Wiegand, M. R.; Maurice, L. D.; Robert, M. B.; Linda, C. G.; Nihar, R. N. VEGF blockade inhibits angiogenesis and re-epithelialization of endometrium. FASEB J., 2008, 22, 3571-3580.
11. Ellis, L.M.; Hicklin, D.J. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat. Rev. Cancer, 2008, 8, 579-591.
12. Ferrara, N.; Kerbel, R.S. Angiogenesis as a therapeutic target. Nature, 2005, 438, 967-974.
13. Chung, A.S.; Lee, J.; Ferrara, N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer, 2010, 10, 505-514.
14. Lassoued, W.; Murphy, D.; Tsai, J.; Oueslati, R.; Thurston, G.; Lee, W.M.F. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol. Ther., 2010, 10(12), 1326-1333.
15. Eicholz, A.; Merchant, S.; Gaya, A.M. Anti-angiogenesis therapies: their potential in cancer management. Onco. Targets Ther., 2010, 3, 69-82.
16. Baffert, F.; Thurston, G.; Rochon-Duck, M.; Le, T.; Brekken, R.; McDonald, D.M. Age-related changes in vascular endothelial growth factor dependency and angiopoietins-1-induced plasticity of adult blood vessels. Circ. Res., 2004, 94, 984-992.
17. Ferrara, N.; Carver-Moore, K.; Chen, H.; Dowd, M.; Lu, L.; O'Shea, K.S.; Powell-Braxton, L.; Hillan, K.J.; Moore, M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature, 1996, 380(6573), 439-442.
18. Ryan, A.M.; Eppler, D.B.; Hagler, K.E.; Bruner, R.H.; Thomford, P.J.; Hall, R.L.; Shopp, G.M.; O'Neill, C.A. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol. Pathol., 1999, 27, 78-86.
19. Liu, H.; Yang, Q.; Radhakrishnan, K.; Whitfield, D.E.; Everhart, C.L.; Parsons- ingerter, P.; Fisher, S.A. Role of VEGF and tissue hypoxia in patterning of neural and vascular cells recruited to the embryonic heart. Dev. Dyn., 2009, 238, 2760-2769.
20. Kalil, R.A.; Salles, F.B.; Giusti, I.I.; Rodrigues, C.G.; Han, S.W.; Sant'Anna, R.T.; Ludwig, E.; Grossman, G.; Prates, P.R.; Sant'anna, J.R.; Teixeira Filho, G.F.; Nardi, N.B.; Nesralla, I.A. VEGF gene therapy for angiogenesis in refractory angina: phase I/II clinical trial. Rev. Bras. Cir. Cardiovasc., 2010, 25(3), 311-321.
21. Henry, T.D.; Annex, B.H.; McKendall, G.R.; Azrin, M.A.; Lopez, J.J.; Giordano, F.J.; Shah, P.K.; Willerson, J.T.; Benza, R.L.; Berman, D.S.; Gibson, C.M.; Bajamonde, A.; Rundle, A.C.; Fine, J.; McCluskey, E.R.; VIVA, Investigators. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation, 2003, 107(10), 1359-1365
22. Inai, T.; Mancuso, M.; Hashizume, H.; Baffert, F.; Haskell, A.; Baluk, P.; Hu-Lowe, D.D.; Shalinsky, D.R.; Thurston, G.; Yancopoulos, G.D.; McDonald, D.M. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol., 2004, 165, 35-52.
23. Baffert, F.; Le, T.; Sennino, B.; Thurston, G.; Kuo, C.J.; Hu-Lowe, D.; McDonald, D.M. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am. J. Physiol. Heart Circ. Physiol., 2005, 290, H547-H559.
24. Saucier, C.; Khoury, H.; Lai, K.M.; Peschard, P.; Dankort, D.; Naujokas, M.A.; Holash, J.; Yancopoulos, G.D.; Muller, W.J.; Pawson, T.; Park, M. The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc. Natl. Acad Sci. USA, 2004, 101(8), 2345-2350.
25. Rini, B.I.; Rathmell, W.K. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin. Cancer Res., 2007, 13, 741s-746s.
26. Tremolada, G.; Lattanzio, R.; Mazzolari, G.; Zerbini, G. The therapeutic potential of VEGF inhibition in diabetic microvascular complications. Am. J. Cardiovasc. Drugs, 2007, 7(6), 393-398.
27. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 1999, 13, 9-22.
28. Fukasawa, M.; Korc, M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic pancreatic cell lines. Clin. Cancer Res., 2004, 10, 3327-3332.
29. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med., 2000, 6(4), 389-395.
30. Baffert, F.; Le, T.; Sennino, B.; Thurston, G.; Kuo, C.J.; Hu-Lowe, D.; McDonald, D.M. Cellular changes in normal blood capillaries undergoing regression after signaling. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H547-H559.
31. Huang, J.; Frischer, J.S.; Serur, A.; Kadenhe, A.; Yokoi, A.; McCrudden, K.W.; New, T.; O'Toole, K.; Zabski, S.; Rudge, J.S.; Holash, J.; Yancopoulos, G.D.; Yamashiro, D.J.; Kandel, J.J. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl. Acad Sci. USA, 2003, 100(13), 7785-7790.
32. Wong, A.K.; Alfert, M.; Castrillon, D.H.; Shen, Q.; Holash, J.; Yancopoulos, G.D.; Chin, L. Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc. Natl. Acad Sci., 2001, 98(13), 7481-7486.
33. Aiello, L.P.; Avery, R.L.; Arrigg, P.G.; Keyt, B.A.; Jampel, H.D.; Shah, S.T.; Pasquale, L.R.; Thieme, H.; Iwamoto, M.A.; Park, J.E. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med., 1994, 131(22), 1480-1487.
34. Sonmez, K.; Drenser, K.A.; Capone, A. Jr.; Trese, M.T. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology, 2008, 115, 1065-1070.
35. Li, W.; Yanoff, M.; Liu, X.; Ye, X. Retinal capillary pericyte apoptosis in early human diabetic retinopathy. Chin. Med. J. (Engl), 1997, 110(9), 659-663.
36. Tam, B.Y.; Wei, K.; Rudge, J.S.; Hoffman, J.; Holash, J.; Park, S.K.; Yuan, J.; Hefner, C.; Chartier, C.; Lee, J.S.; Jiang, S.; Nayak, N.R.; Kuypers, F.A.; Ma, L.; Sundram, U.; Wu, G.; Garcia, J.A.; Schrier, S.L.; Maher, J.J.; Johnson, R.S.; Yancopoulos, G.D.; Mulligan, R.C.; Kuo, C.J. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat. Med., 2006, 12(7), 793-800.
37. Launay-Vacher, V.; Deray, G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anti-Cancer Drugs, 2009, 21, 81-82.
38. Wulff, C.; Wilson, H.; Rudge, J.S.; Wiegand, S.J.; Lunn, S.F.; Fraser, H.M. Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trapA40. J. Clin. Endocrinol. Metab., 2001, 86, 3377-3386.
39. Nolan, A.; Weiden, M.D.; Thurston, G.; Gold, J.A. Vascular endothelial growth factor blockade reduces plasma cytokines in a murine model of polymicrobial sepsis. Inflammation, 2004, 28(5), 271-278.
40. Ku, D.D.; Zaleski, J.K.; Liu, S.; Brock, T.A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol., 1993, 265, H586-H592.
41. Bates, D.O.; Curry, F.E. Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am. J. Physiol., 1997, 273, H687-H694.
42. Roberts, W.G.; Palade, G.E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci., 1995, 108(Pt6), 2369-2379.
43. Antonetti, D.; Lieth, E.; Barber, A.; Gardner, T. Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin. Ophthalmol., 1999, 14(4), 240-248.
44. Xia, Y-P.; Li, B.; Hylton, D.; Yancopoulos, G.D.; Rudge, J.S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood, 2003, 102, 161-168.
45. Wulff, C.; Wilson, H.; Wiegand, S.J.; Rudge, J.S.; Fraser, H.M. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor trap R1R. Endocrinology, 2002, 143(7), 2797-2807.
46. Verheul, H.M.; Hammers, H.; van Erp, K.; Wei, Y.; Sanni, T.; Salumbides, B.; Qian, D.Z.; Yancopoulos, G.D.; Pili, R. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin. Cancer Res., 2007, 13, 4201-4208.
47. Izzedine, H.; Massard, C.; Spano, J.P.; Goldwasser, F.; Khayat, D.; Soria, J.C. VEGF signaling inhibition-induced proteinuria: mechanisms, significance and management. Eur. J. Cancer, 2010, 46, 439-448.
48. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S.D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Bailey, K.; Fandl, J.P.; Daly, T.; Wiegand, S.J.; Yancopoulos, G.D.; Rudge, J.S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad Sci. USA, 2002, 99(17), 11393-11398.
49. Tew, W.P.; Gordon, M.; Murren, J.; Dupont, J.; Pezzulli, S.; Aghajanian, C.; Sabbatini, P.; Mendelson, D.; Schwartz, L.; Gettinger, S.; Psyrri, A.; Cedarbaum, J.M.; Spriggs, D.R. Phase I study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin. Cancer Res., 2010, 16(1), 358-366.
50. Cursiefen, C.; Chen, L.; Borges, L.P.; Jackson, D.; Cao, J.; Radziejewski, C.; D'Amore, P.A.; Dana, M.R.; Wiegand, S.J.; Streilein, J.W. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest., 2004, 113, 1040-1050.
51. Kim, E.S.; Serur, A.; Huang, J.; Manley, C.A.; McCrudden, K.W.; Frischer, J.S.; Soffer, S.Z.; Ring, L.; New, T.; Zabski, S.; Rudge, J.S.; Holash, J.; Yancopoulos, G.D.; Kandel, J.J.; Yamashiro, D.J. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad Sci. USA, 2002, 99(17), 11399-11404.
52. Rudge, J.S.; Holash, J.; Hylton, D.; Russell, M.; Jiang, S.; Leidich, R.; Papadopoulos, N.; Pyles, E.A.; Torri, A.; Wiegand, S.J.; Thurston, G.; Stahl, N.; Yancopoulos, G.D. VEGF trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc. Natl. Acad Sci. USA, 2007, 104(47), 18363-18370.
53. Dixon, J.A.; Oliver, S.C.; Olson, J.L.; Mandava, N. VEGF Trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opin. Investig. Drugs, 2009, 18(10), 1573-1580.
54. Fricke, I.; Mirza, N.; Dupont, J.; Lockhart, C.; Jackson, A.; Lee, J.H.; Sosman, J.A.; Gabrilovich, D.I. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res., 2007, 13, 4840-4848.
55. Bianco F, Basini G, Grasselli F. Angiogenic activity of swine granulosa cells: effects of hypoxia and vascular endothelial growth factor trap R1R2, a VEGF blocker. Domest. Anim. Endocrinol., 2005, 28, 308-319.
56. Thomas, F.H.; Telfer, E.E.; Fraser, H.M. Expression of anti-mullerian hormone protein during early follicular development in the primate ovary in vivo is influenced by suppression of gonadotropin secretion and inhibition of vascular endothelial growth factor. Endocrinology, 2007, 148, 2273-2281.
57. Taylor, P.D.; Wilson, W.; Hillier, S.G.; Wiegand, S.J.; Fraser, H.M. Effects of inhibition of vascular endothelial growth factor at time of selection on follicular angiogenesis, expansion, development and atresia in the marmoset. Mol. Hum. Reprod., 2007, 13(10), 729-736.
58. Fraser, H.M.; Morris, K.D.; Wiegand, S.J.; Wilson, H. Inhibition of vascular endothelial growth factor during the postovulatory period prevents pregnancy in the marmoset. Contraception, 2010, 82, 572-578.
59. Lu, C.; Thaker, P.H.; Lin, Y.G.; Spannuth, W.; Landen, C.N.; Merritt, W.M.; Jennings, N.B.; Langley, R.R.; Gershenson, D.M.; Yancopoulos, G.D.; Ellis, L.M.; Jaffe, R.B.; Coleman, R.L.; Sood, A.K. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am. J. Obstet. Gynecol., 2008, 198, 477.e1-477.e10.
60. Rodewald, M.; Herr, D.; Fraser, H.M.; Hack, G.; Kreienberg, R.; Wulff, C. Regulation of tight junction proteins occludin and claudin 5 in the primate ovary during the ovulatory cycle and after inhibition of vascular endothelial growth factor. Mol. Hum. Reprod., 2007, 13(11), 781-789.
61. Hu, L.; Hofmann, J.; Holash, J.; Yancopoulos, G.D.; Sood, A.K.; Jaffe, R.B. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin. Cancer Res., 2005, 11(19), 6966-6971.
62. Lal, D.; Park, J.A.; Demock, K.; Marinaro, J.; Perez, A.M.; Lin, M.H.; Tian, L.; Mashtare, T.J.; Murphy, M.; Prey, J.; Wetzler, M.; Fetterly, G.J.; Wang, E.S. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Mol. Cancer Ther., 2010, 9, 2737-2751.
63. Byrne, A.T.; Ross, L.; Holash, J.; Nakanishi, M.; Hu, L.; Hofmann, J.I.; Yancopoulos, G.D.; Jaffe, R.B. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res., 2003, 9, 5721-5728.
64. Jeon, B.H.; Jang, C.; Han, J.; Kataru, R.P.; Piao, L.; Jung, K.; Cha, H.J.; Schwendener, R.A.; Jang, K.Y.; Kim, K.S.; Alitalo, K.; Koh, G.Y. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res., 2008, 68, 1100-1109.
65. Fan, X.; Krieg, S.; Kuo, C.J.; Wiegand, S.J.; Rabinovitch, M.; Druzin, M.L.; Brenner, R.M.; Giudice, L.C.; Nayak, N.R. VEGF blockade inhibits angiogenesis and re-epithelialization of endometrium. FASEB J., 2008, 22, 3571-3580.
66. Aberdeen, G.W.; Wiegand, S.J.; Bonagura, T.W. Jr.; Pepe, G.J.; Albrecht, E.D. Vascular endothelial growth factor mediates the estrogen-induced breakdown of tight junctions between and increase in proliferation of microvessel endothelial cells in the baboon endometrium. Endocrinology, 2008, 149(12), 6076-6083.
67. Fraser, H.M.; Wilson, H.; Silvestri, A.; Morris, K.D.; Wiegand, S.J. The role of vascular endothelial growth factor and estradiol in the regulation of endometrial angiogenesis and cell proliferation in the marmoset. Endocrinology, 2008, 149(9), 4413-4420.
68. Mancino, A.; Mancino, M.G.; Glaser, S.S.; Alpini, G.; Bolognese, A.; Izzo, L.; Francis, H.; Onori, P.; Franchitto, A.; Ginanni-Corradini, S.; Gaudio, E.; Alvaro, D. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig. Liver Dis., 2009, 41, 156-163.
69. Frischer, J.S.; Huang, J.; Serur, A.; Kadenhe-Chiweshe, A.; McCrudden, K.W.; O'Toole, K.; Holash, J.; Yancopoulos, G.D.; Yamashiro, D.J.; Kandel, J.J. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int. J. Oncol., 2004, 25(3), 549-553.
70. Gomez-Manzano, C.; Holash, J.; Fueyo, J.; Xu, J.; Conrad, C.A.; Aldape, K.D.; de Groot, J.F.; Bekele, B.N.; Yung, W.K. VEGF trap induces anti-glioma effect at different stages of disease. Neuro. Oncol., 2008, 10(6), 940-945.
71. Luque, G.M.; Perez-Millan, M.I.; Ornstein, A.M.; Cristina, C.; Becu-Villalobos, D. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. J. Pharmacol. Exp. Ther., 2011, 337, 766-744.
72. Kadenhe-Chiweshe, A.; Papa, J.; McCrudden, K.W.; Frischer, J.; Bae, J.O.; Huang, J.; Fisher, J.; Lefkowitch, J.H.; Feirt, N.; Rudge, J.; Holash, J.; Yancopoulos, G.D.; Kandel, J.J.; Yamashiro, D.J. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol. Cancer Res., 2008, 6, 1-9.
73. Le, X.F.; Mao, W.; Lu, C.; Thornton, A.; Heymach, J.V.; Sood, A.K.; Bast, R.C. Jr. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle, 2008, 23(7), 3747-3758.
74. Wachsberger, P.R.; Burd, R.; Cardi, C.; Thakur, M.; Daskalakis, C.; Holash, J.; Yancopoulos, G.D.; Dicker, A.P. VEGF trap in combination with radiotherapy improves tumor control in U87 glioblastoma. Int. J. Radiation Oncol. Biol. Phys., 2007, 67(5), 1526-1537.
75. Parvadia, J.K.; Keswani, S.G.; Vaikunth, S.; Maldonado, A.R.; Marwan, A.; Stehr, W.; Erwin, C.; Uzvolgyi, E.; Warner, B.W.; Yamano, S.; Taichman, N.; Crombleholme, T.M. Role of VEGF in small bowel adaptation after resection: the adaptive response is angiogenesis dependent. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 293, G591-G598.
76. Saishin, Y.; Saishin, Y.; Takahashi, K.; Lima e Silva, R.; Hylton, D.; Rudge, J.S.; Wiegand, S.J.; Campochiaro, P.A. VEGF-trapR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J. Cell Physiol., 2003, 195, 241-248.
77. Cao, J.; Zhao, L.; Li, Y.; Liu, Y.; Xiao, W.; Song, Y.; Luo, L.; Huang, D.; Yancopoulos, G.D.; Wiegand, S.J.; Wen, R. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest. Ophthalmol. Vis. Sci., 2010, 51, 6009-6017.
78. Oliveira, H.B.; Sakimoto, T.; Javier, J.A.; Azar, D.T.; Wiegand, S.J.; Jain, S.; Chang, J.H. VEGF TrapR1R2 suppresses experimental corneal angiogenesis. Eur. J. Ophthalmol., 2010, 20, 48-54.
79. Dalal, S.; Berry, A.M.; Cullinane, C.J.; Mangham, D.C.; Grimer, R.; Lewis, I.J.; Johnston, C.; Laurence, V.; Burchill, S.A. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin. Cancer Res., 2005, 11, 2364-2378.
80. Riely, G.J.; Miller, V.A. Vascular endothelial growth factor trap in non-small cell lung cancer. Clin. Cancer Res., 2007, 13, 4623s-4627s.
81. Lockhart, A.C.; Rothenberg, M.L.; Dupont, J.; Cooper, W.; Chevalier, P.; Sternas, L.; Buzenet, G.; Koehler, E.; Sosman, J.A.; Schwartz, L.H.; Gultekin, D.H.; Koutcher, J.A.; Donnelly, E.F.; Andal, R.; Dancy, I.; Spriggs, D.R.; Tew, W.P. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J. Clin. Oncol., 2009, 28, 207-214.
82. National Institutes of Health. A study to evaluate the effects of aflibercept on QTc interval in cancer patients (QUTIE). Available at: http://clinicaltrials.gov/ct2/show/NCT00876044.
83. US National Institutes of Health. A phase I study of intravenous aflibercept in combination with docetaxel in Japanese cancer patients. http://clinicaltrials.gov/ct2/show/NCT00545246. Accessed July 31, 2011.
84. US National Institutes of Health. A phase I study of intravenous aflibercept in combination with S-1 in Japanese cancer patients. http://clinicaltrials.gov/ct2/show/NCT00479076. Accessed July 31, 2011.
85. de Groot, J.F.; Lamborn, K.R.; Chang, S.M.; Gilbert, M.R.; Cloughesy, T.F.; Aldape, K.; Yao, J.; Jackson, E.F.; Lieberman, F.; Robins, H.I.; Mehta, M.P.; Lassman, A.B.; Deangelis, L.M.; Yung, W.K.; Chen, A.; Prados, M.D.; Wen, P.Y. Phase II study of aflibercept in recurrent malignant glioma: a North American brain tumor consortium study. J. Clin. Oncol., 2011, 29(19), 2689-2695.
86. Leighl, N.B.; Raez, L.E.; Besse, B.; Rosen, P.J.; Barlesi, F.; Massarelli, E.; Gabrail, N.; Hart, L.L.; Albain, K.S.; Berkowitz, L.; Melnyk, O.; Shepherd, F.A.; Sternas, L.; Ackerman, J.; Shun, Z.; Miller, V.A.; Herbst, R.S. A multicenter, phase 2 study of vascular endothelial growth factor trap (aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J. Thorac. Oncol., 2010, 5, 1054-1059.
87. Alvarez, R.H.; Valero, V.; Hortobagyi, G.N. Emerging targeted therapies for breast cancer. J. Clin. Oncol., 2010, 28(20), 3366-3379.
88. Twardowski, P.; Stadler, W.M.; Frankel, P.; Lara, P.N.; Ruel, C.; Chatta, G.; Heath, E.; Quinn, D.I.; Gandara, D.R. Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California cancer consortium trial. Urology, 2010, 76, 923-926.
89. US National Institutes of Health. A study of aflibercept and modified FOLFOX6 as first-line treatment in patients with metastatic colorectal cancer (AFFIRM). Http://clinicaltrials.gov/ ct2/show/NCT00851084. Accessed July 31, 2011.
90. Tew, W.P.; Colombo, N.; Ray-Coquard, I. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. J. Clin. Oncol., 2007, 25 Abstract 5508.
91. Reichert, J.M. Antibody-based therapeutics to watch in 2011. mABs, 2011, 3(1), 76-99
92. Kindler, H.L.; Niedzwiecki, D.; Hollis, D.; Sutherland, S.; Schrag, D.; Hurwitz, H.; Innocenti, F.; Mulcahy, M.F.; O'Reilly, E.; Wozniak, T.F.; Picus, J.; Bhargava, P.; Mayer, R.J.; Schilsky, R.L.; Goldberg, R.M. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the cancer and leukemia group B (CALGB 80303). J. Clin. Oncol., 2010, 28(22), 3617-3622.
93. US National Institutes of Health. A study of aflibercept versus placebo in patients with second-line docetaxel for locally advanced or metastatic non-small-cell lung cancer (VITAL). http://clinical trials.gov/ct2/show/NCT00532155. Accessed July 31, 2011.
94. Available at: http://www.inpharm.com/news/150688/sanofi-regene ron-aflibercept-phase-iii. Accessed July 31, 2011.
95. US National Institutes of Health. Aflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE). http://clinicaltrials.gov/ct2/show/NCT00519285. Accessed July 31,2011
96. US National Institutes of Health. A study of aflibercept versus placebo in combination with irinotecan and 5-FU in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin based regimen (VELOUR). Available at: http://clinical trials.gov.ct2/show/NCT00561470. Accessed July 31, 2011.
97. Van Cutsem, E.; Dicato, M.; Geva, R.; Arber, N.; Bang, Y.; Benson, A.; Cervantes, A.; Diaz-Rubio, E.; Ducreux, M.; Glynne-Jones, R.; Grothey, A.; Haller, D.; Haustermans, K.; Kerr, D.; Nordlinger, B.; Marshall, J.; Minsky, B.D.; Kang, Y.K.; Labianca, R.; Lordick, F.; Ohtsu, A.; Pavlidis, N.; Roth, A.; Rougier, P.; Schmoll, H.J.; Sobrero, A.; Tabernero, J.; Van de Velde, C.; Zalcberg, J. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann. Oncol., 2011, 22(Suppl 5), v1-9.
98. US National Institutes of Health. A study of intravenous aflibercept with docetaxel in Chinese patients with solid tumors. Available at: http://clinicaltrials.gov/ct2/show/NCT01148615. Accessed July 31, 2011.
99. Michels, S.; Rosenfeld, P.J.; Puliafito, C.A.; Marcus, E.N.; Venkatraman, A.S. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Ophthalmology, 2005, 112, 1035-1047.
100. Nguyen, Q.D.; Shah, S.M.; Hafiz, G.; Quinlan, E.; Sung, J.; Chu, K.; Cedarbaum, J.M.; Campochiaro, P. A.; CLEAR-AMD 1 Study Group. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology, 2006, 113(9), 1522el1521-14.
101. Nguyen, Q.D.; Shah, S.M.; Browning, D.J.; Hudson, H.; Sonkin, P.; Hariprasad, S.M.; Kaiser, P.; Slakter, J.S.; Haller, J.; Do, D.V.; Mieler, W.F.; Chu, K.; Yang, K.; Ingerman, A.; Vitti, R.L.; Berliner, A.J.; Cedarbaum, J.M.; Campochiaro, P.A. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology, 2009, 116, 2141-2148.
102. Brown, D.M.; Heier, J.S.; Ciulla, T.; Benz, M.; Abraham, P.; Yancopoulos, G.; Stahl, N.; Ingerman, A.; Vitti, R.; Berliner, A.J.; Yang, K.; Nguyen, Q.D.; CLEAR-IT 2 Investigators. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology, 2011, 118, 1089-1097.
103. Heier, J.S.; Boyer, D.; Nguyen, Q.D.; Marcus, D.; Roth, D.B.; Yancopoulos, G.; Stahl, N.; Ingerman, A.; Vitti, R.; Berliner, A.J.; Yang, K.; Brown, D.M.; CLEAR-IT 2 Investigators. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology, 2011, 118, 1098-1106.
104. Do, D.V.; Nguyen, Q.D.; Shah, S.M.; Browning, D.J.; Haller, J.A.; Chu, K.; Yang, K.; Cedarbaum, J.M.; Vitti, R.L.; Ingerman, A.; Campochiaro, P.A. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor trap-eye in patients with diabetic macular oedema. Br. J. Ophthalmol., 2009, 93, 144-149.